Iterum therapeutics plc (ITRM)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-98,650

-103,130

-103,746

-97,381

-85,490

-77,056

0

0

0

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

156

152

150

146

140

136

0

0

0

Share-based compensation expense

2,230

2,173

2,086

1,999

1,681

1,290

0

0

0

Gain on short-term investments

-

125

0

0

0

-

-

-

-

Non-cash gain on short-term investments

-

-

-

-

264

278

0

0

0

Interest on short-term investments

-

5

0

0

0

-

-

-

-

Amortization of debt discount and deferred financing costs

1,878

362

0

0

0

-

-

-

-

Private placement transaction costs included in financing activities

0

-

-

-

-

-

-

-

-

Adjustments to fair value of derivatives

0

-

-

-

-

-

-

-

-

Other

-911

-752

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-2,059

-2,471

2,020

1,539

1,818

3,613

0

0

0

Other assets

-

-

-

-

-

2,273

0

0

0

Accounts payable

126

11,446

11,785

1,953

2,562

849

0

0

0

Accrued expenses

-2,025

5,851

9,753

9,901

4,042

3,072

0

0

0

Income taxes

110

123

131

107

172

120

0

0

0

Other liabilities

0

-

-

-

54

242

0

0

0

Net cash used in operating activities

-91,223

-78,885

-82,694

-84,780

-79,303

-75,890

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

-

24

43

59

79

90

0

0

0

Purchases of short-term investments

-

-

-

-

-

96,493

0

0

0

Proceeds from sale of short-term investments

-

40,125

76,650

93,875

107,275

87,925

0

0

0

Net cash provided by investing activities

-

40,101

68,849

51,050

17,075

-8,658

0

0

0

Cash flows from financing activities:
Repayments of long-term debt

0

-

-

-

-

-

-

-

-

Proceeds from private placement, net of transactions costs

0

-

-

-

-

-

-

-

-

Proceeds from exercise of share options

-

60

0

0

0

-

-

-

-

Net cash provided by financing activities

44,848

-974

3,104

67

88,715

120,842

0

0

0

Effect of exchange rates on cash and cash equivalents

-12

-22

0

0

0

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

-41,376

-39,780

-10,745

-33,690

26,345

36,186

0

0

0

Supplemental Disclosure of Cash Flow Information:
Interest paid

1,343

1,399

0

0

0

-

-

-

-

Exchangeable Notes
Amortization of debt discount and deferred financing costs

0

-

-

-

-

-

-

-

-

Interest on exchangeable notes - non-cash

0

-

-

-

-

-

-

-

-

Series B Convertible Preferred Shares
Proceeds from issuance of convertible preferred shares

-

-

-

-

-

32,175

0

0

0